Amgen's Reticence On Parsabiv Complete Response Letter Revives Transparency Issue

But Amgen is in good company when it comes to companies that choose not to disclose the contents of complete response letters, data from the Pink Sheet's FDA Performance Tracker show. Merck especially holds such information close.